Abstract：
The hamstring tendon (HT) autograft is currently the most widely utilised autograft option for anterior cruciate ligament (ACL) reconstruction. However, recent studies endorse the peroneus longus tendon (PLT) autograft as a viable alternative. To evaluate this, we systematically reviewed randomised controlled trials (RCTs) to compare the efficacy of PLT against HT autografts. Our search encompassed Cochrane, Embase, OVID, PubMed, and Scopus databases for RCTs comparing outcomes of PLT and HT autografts in ACL reconstruction. Primary outcomes included Lysholm and International Knee Documentation Committee (IKDC) scores, while secondary outcomes involved American Orthopaedic Foot and Ankle Society (AOFAS) scores, graft diameters and donor-site complications. Statistical analysis was performed using Review Manager 5.4 (Cochrane Collaboration) and heterogeneity was assessed with I2 statistics. 683 patients from 6 RCTs were included, with 338 (49.5%) patients treated with PLT autografts. Follow-up ranged from 12 to 30 months. Despite lower preoperative Lysholm scores in the PLT group, no significant differences were observed at 6 and 12 months. Although preoperative and 6-month IKDC scores were lower in the PLT group, no significant differences were found at 12 and 24 months. AOFAS scores showed no significant preoperative difference, but slightly lower scores were noted in the PLT group at 12 or 24 months. There was no significant difference in graft diameter, while donor-site complications were fewer in the PLT group. In summary, the PLT autograft is a promising and non-inferior alternative to the HT autograft, demonstrating equivalent outcomes in patient-reported knee and ankle metrics, comparable graft diameters and fewer donor-site complications.
摘要：
绳肌腱（HT）自体移植是目前用于前交叉韧带（ACL）重建的最广泛使用的自体移植选择。然而,最近的研究表明腓骨长肌腱（PLT）是一种可行的替代方法。为了评估这一点，我们系统回顾了随机对照试验(RCTs),以比较PLT对HT自体移植物的疗效.我们的搜索包括Cochrane,Embase,OVID,PubMed,和Scopus数据库，用于比较PLT和HT自体移植在ACL重建中的结果。主要结果包括Lysholm和国际膝关节文献委员会（IKDC）评分，次要结局涉及美国骨科足踝协会（AOFAS）评分，移植物直径和供体部位并发症。使用ReviewManager5.4（CochraneCollaboration）进行统计分析，并使用I2统计量评估异质性。纳入6个RCT的683例患者，338例（49.5%）患者接受PLT自体移植物治疗。随访时间为12～30个月。尽管PLT组术前Lysholm评分较低,在6个月和12个月时没有观察到显著差异.尽管PLT组术前和6个月IKDC评分较低,在12个月和24个月时没有发现显著差异.AOFAS评分术前差异无统计学意义，但PLT组在12个月或24个月时得分略低.移植物直径无显著差异，而PLT组供体部位并发症较少。总之,PLT自体移植物是HT自体移植物的一种有前途且非劣质的替代品，显示患者报告的膝关节和踝关节指标的等效结果，相当的移植物直径和较少的供体部位并发症。
